Abstract Number: 1319 • ACR Convergence 2020
Disease Activity and Mental Health of as Patients: A Cross-section Study with Self-assessments Based on Smart System of Disease Management (SSDM) Mobile Tools
Background/Purpose: WHO survey showed that the prevalence of anxiety and depression in Chinese population and Chinese patients with chronic diseases were between 3.1% - 4.2%…Abstract Number: 1600 • ACR Convergence 2020
Relationship Between Electronic Health Record Vendor and Performance on Patient-reported Outcome Quality Measures in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Background/Purpose: Routine collection of disease activity and patient reported outcomes (PROs) such as functional status assessment in rheumatoid arthritis (RA) are nationally endorsed quality measures…Abstract Number: 1880 • ACR Convergence 2020
Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis
Background/Purpose: Treatments for ankylosing spondylitis (AS) have been shown to improve patient-reported outcome (PRO) measures in clinical studies; however, healthcare decision makers have limited ability…Abstract Number: 0147 • ACR Convergence 2020
The Interpretation of Patient-reported Outcomes in Rheumatoid Arthritis: Do Clinical Trials Adequately Evaluate Meaningful Improvements for Patients?
Background/Purpose: The importance of patient-relevant outcomes, such as pain, fatigue and physical functioning, has been long established in the field of rheumatoid arthritis (RA). Patient-reported…Abstract Number: 0236 • ACR Convergence 2020
Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial
Background/Purpose: The subcutaneous (SC) formulation of CT-P13 received marketing authorization for RA from the EMA by demonstrating non-inferiority compared to CT-P13 intravenous for efficacy in…Abstract Number: 0360 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from German Observational Study
Background/Purpose: Several studies have shown an negative association between smoking status and psoriatic arthritis (PsA) clinical outcomes1,2. The German non-interventional study AQUILA provides real-world data…Abstract Number: 0884 • ACR Convergence 2020
Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: There is no single accepted measure of low/minimal disease activity (LDA/MDA) for patients with PsA; thus, describing the characteristics of real-world patients meeting different…Abstract Number: 1214 • ACR Convergence 2020
Association Between Changes in C-reactive Protein at Week 12 and Patient-Reported Outcomes at Week 24 with Sarilumab Therapy Across Three Pivotal Phase 3 Studies
Background/Purpose: Evaluation of response to RA therapy at 12 weeks after initiation is recommended in treatment guidelines. CRP response after 12 weeks of therapy may…Abstract Number: 1322 • ACR Convergence 2020
Prevalence and Associated Factors of Sleep Disorders in Patients with Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS)
Background/Purpose: Sleep is an essential health aspect that is often impacted in patients with axial spondyloarthritis (axSpA). This analysis aims to assess the prevalence and…Abstract Number: 1601 • ACR Convergence 2020
Pilot Testing Supports Utility of a Point-of-Care Dashboard to Enhance Patient and Clinician Partnerships in the Management of RA
Background/Purpose: Increasing evidence exists that health outcomes are improved when people living with a chronic condition partner with their clinicians to coproduce their care based…Abstract Number: 1889 • ACR Convergence 2020
Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients
Background/Purpose: The Patient Reported Outcomes Measurement Information System 29-Item Profile Measure (PROMIS-29) is a generic measure of health-related quality of life (HRQOL) that has seven…Abstract Number: 2692 • 2015 ACR/ARHP Annual Meeting
The Patients Evaluation of Pain and Disease Activity As Well As Improvement during One-Year Follow-up on Etanercept Treatment Is Highly Associated to Subjective Factors and Not to Objective Assessments Including Ultrasound
Background/Purpose: Patient reported outcomes (PROs) are important for evaluation of treatment response in patients with rheumatoid arthritis (RA). Ultrasound (US) is a sensitive method for…
- « Previous Page
- 1
- …
- 41
- 42
- 43